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Abstract
Background: Naturally occurring CD4
+CD25
+Foxp3
+ regulatory T (Treg) cells develop in the thymus and represent a mature
T cell subpopulation critically involved in maintaining peripheral tolerance. The differentiation of Treg cells in the thymus
requires T cell receptor (TCR)/CD28 stimulation along with cytokine-promoted Foxp3 induction. TCR-mediated nuclear
factor kappa B (NF-kB) activation seems to be involved in differentiation of Treg cells because deletion of components of
the NF-kB signaling pathway, as well as of NF-kB transcription factors, leads to markedly decreased Treg cell numbers in
thymus and periphery.
Methodology/Principal Findings: To investigate if Treg cell-intrinsic NF-kB activation is required for thymic development
and peripheral homeostasis of Treg cells we used transgenic (Tg) mice with thymocyte-specific expression of a stable IkBa
mutant to inhibit NF-kB activation solely within the T cell lineage. Here we show that Treg cell-intrinsic NF-kB activation is
important for the generation of cytokine-responsive Foxp3
2 thymic Treg precursors and their further differentiation into
mature Treg cells. Treg cell development could neither be completely rescued by the addition of exogenous Interleukin 2
(IL-2) nor by the presence of wild-type derived cells in adoptive transfer experiments. However, peripheral NF-kB activation
appears to be required for IL-2 production by conventional T cells, thereby participating in Treg cell homeostasis. Moreover,
pharmacological NF-kB inhibition via the IkB kinase b (IKKb) inhibitor AS602868 led to markedly diminished thymic and
peripheral Treg cell frequencies.
Conclusion/Significance: Our results indicate that Treg cell-intrinsic NF-kB activation is essential for thymic Treg cell
differentiation, and further suggest pharmacological NF-kB inhibition as a potential therapeutic approach for manipulating
this process.
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Introduction
Regulatory T (Treg) cells comprise a functionally distinct T cell
lineage that plays a crucial role in maintaining peripheral
tolerance and preventing autoimmunity by suppressing prolifera-
tion, cytokine secretion and activation of conventional T cells
[1,2,3,4,5,6,7,8]. Treg cells can be divided into two major
subgroups: naturally occurring Treg cells (nTreg) that develop
within the thymus [9], and induced Treg cells (iTreg) that are
generated by conversion from conventional T cells (Tconv) in the
periphery by a variety of different stimuli [10,11,12,13].
The best-characterized subtype, however, are the thymic-
derived naturally occurring Treg cells that comprise about 5–
10% of peripheral CD4
+ T cells in healthy humans and mice.
Treg cells constitutively express the IL-2 receptor a chain (CD25)
[1] as well as the transcription factor Foxp3 [14,15,16]. Rather
than governing Treg cell lineage commitment [15,16], Foxp3 acts
more like a Treg cell stabilizing factor maintaining Treg cell-
specific gene expression that was initially induced by other
transcription factors [17,18,19]. Nevertheless, Foxp3 expression
is essential for the suppressive function of Treg cells, because loss-
of-function foxp3 mutations result in strong hyper-lymphoprolifer-
ative disease and multi-organ autoimmunity in humans (IPEX
syndrome, immune dysregulation, polyendocrinopathy, enteropa-
thy, X-linked) [20,21] and mice (scurfy mice) [22,23].
So far the signaling pathways involved in the generation of
naturally occurring Treg cells remain to be completely elucidated.
It is generally believed that Treg cells develop within the thymus
through interaction of high-affinity TCRs with cognate self-
antigens presented by thymic epithelial cells [24,25,26]. However,
signaling through the TCR alone is not sufficient. Several
additional signals, including CD28 costimulation [27,28,29] as
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[30,31,32,33,34], are also necessary. Additionally, STAT5 (signal
transducer and activator of transcription 5) activation as a result of
proximal cc-receptor signaling appears to be required for thymic
Treg cell generation [35,36,37]. Based on these observations and
additional data, a two-step model for the thymic development of
regulatory T cells has been suggested: in the first step, developing
thymocytes following a strong TCR/CD28 signal upregulate
CD25 and other components of the IL-2 signaling pathway. This
enables these CD4
+CD25
hiFoxp3
2 Treg precursor cells in a
second TCR-independent step to respond to IL-2 resulting in
STAT5 activation, thereby inducing Foxp3 expression and
completing Treg cell development [38,39].
The activation of the NF-kB pathway as a downstream
signaling event following TCR/CD28 ligation has been implicated
in thymic Treg cell development [40]. The mammalian NF-kB
transcription factor family consists of five members (p50/p105,
p65/RelA, c-Rel, p52/p100, RelB) which can form both homo-
and heterodimers. In resting cells, NF-kB dimers are kept inactive
in the cytoplasm through the association with inhibitory IkB
proteins such as IkBa,I kBb and IkBe as well as p105 and p100 as
precursor forms of NF-kB1 (p50) and NF-kB2 (p52), respectively.
Upon cell activation the IKK-complex, consisting of the two
catalytic subunits IKKa and IKKb, and the regulatory subunit
IKKc (NEMO), gets activated, subsequently phosphorylates IkB
followed by its proteasomal degradation, thereby allowing the NF-
kB dimers to translocate into the nucleus. There are two known
pathways of NF-kB activation: the ‘‘classical’’ pathway, mediated
by IKKb activating p50, p65 and c-Rel, in contrast to the ‘‘non-
canonical’’ one which involves IKKa recruiting p52 and RelB
[41,42].
In conventional T cells, ‘‘classical’’ NF-kB activation following
TCR/CD28 ligation is mediated by PKCh stimulating
CARMA1, Bcl10, and MALT to form the so called CBM-
complex. This complex phosphorylates and thereby activates
IKKb, which in turn phosphorylates IkB, an event resulting in its
proteasomal degradation and subsequent activation of NF-kB
[43,44,45,46,47]. Mice deficient in either PCKh, Bcl10, or
CARMA1 [48,49,50,51], as well as mice lacking IKKb or NF-
kB/Rel proteins such as p50 and c-Rel [52,53,54,55,56] show
impaired Treg cell development leaving other T cell subpopu-
lations unchanged. Recently, Long et al. showed that modulation
of NF-kB activation influenced Foxp3 expression. Activation of
NF-kB through transgenic expression of a constitutively active
IKKb (IKKEE Tg) increased the number of thymic Foxp3
+ Treg
cells, whereas inhibition of NF-kB resulting from transgenic
expression of a stabilized IkBa (IkBa-SR Tg) decreased the
thymic Treg cell number [57].
However, it remains unclear whether Treg cell-intrinsic NF-kB
activation is essential for the development of early Treg precursor
cells and/or for the survival of fully differentiated Treg cells.
Additionally, it cannot be excluded that insufficient IL-2 supply
may account for the reduced Treg cell numbers in mice with
attenuated NF-kB activity. Using IkBa-‘‘SuperRepressor’’ trans-
genic mice (IkBa-SR Tg) we provide evidence that ‘‘classical’’ NF-
kB activation is critical for the generation of cytokine-responsive
thymic Treg precursor cells. Furthermore, IL-2 supplementation
as well as adoptive transfer experiments demonstrated that the
failure in Treg cell differentiation is predominantly due to a cell-
intrinsic defect. Finally, systemic pharmacological IKKb inhibition
led to significantly decreased CD4
+CD25
+Foxp3
+ Treg frequen-
cies in thymus and spleen, suggesting NF-kB inhibition as a
potential therapeutic approach to manipulate Treg cell differen-
tiation.
Results
Reduced thymic and peripheral Treg cell numbers in
IkBa-SR Tg mice
To investigate the role of classical NF-kB activation for the
development of naturally occurring Treg cells, we used a
transgenic mouse model expressing a mutated and thereby
stabilized form of IkBa (IkBa-‘‘SuperRepressor’’) under control
of the proximal lck-promoter (IkBa-SR Tg) to achieve high levels
of thymocyte-specific expression as shown by western blot analyses
(Figure S1A and [58] Material and Methods S1). The transgene
expression could also be detected in peripheral lymphocytes in the
spleen, but to a lesser extent (Figure S1A). Nuclear extracts of
thymocytes from IkBa-SR Tg mice showed a markedly attenuated
NF-kB nuclear DNA binding activity by electromobility shift assay
(EMSA, Materials and Methods S1) when cells were directly
analyzed ex vivo, and even more pronounced, after 1 hour of
mitogen stimulation in vitro (Figure S1B). Consistent with these
data, ELISA analyses (Material and Methods S1) revealed that
nuclear extracts from IkBa-SR Tg mice contained significantly
less activated p65/RelA and c-Rel after mitogen stimulation.
Activated p50 was reduced by about 30% in IkBa-SR Tg mice
compared to wild-type controls (Figure S1C).
Consistent with the previous description of the IkBa-SR Tg
mice [58], the thymus from double-transgenic mice was of normal
size and the absolute thymocyte numbers were not significantly
different compared to wild-type mice. Flow cytometric analyses
further revealed normal frequencies of CD4
+CD8
+ double-positive
(DP), as well as CD4
+ single-positive (SP) thymocytes. As
previously reported, there was a strong decrease in the numbers
of CD8SP thymocytes. In the spleens of IkBa-SR Tg mice
peripheral CD8
+ T lymphocyte numbers were even more severely
reduced (Figure 1A, C upper panel). Consistently, we observed a
prominent loss of peripheral CD4
+ and even more pronounced
CD8
+ T lymphocytes in IkBa-SR Tg mice (Figure 1C, upper
panel). Of note, the frequency of CD25
+Foxp3
2CD4SP thymo-
cytes, a subpopulation which is enriched in cytokine-dependent
Treg precursor cells [38,39,59], was markedly reduced in IkBa-
SR Tg mice (Figure 1A, lower panel). The frequencies, as well as
absolute cell numbers of mature thymic CD25
+Foxp3
+CD4SP
Treg cells were also significantly diminished compared to wild-
type controls (Figure 1A, lower panel, B). In the IkBa-SR Tg
mice peripheral splenic CD25
+Foxp3
+CD4
+ Treg cells were only
slightly reduced in their frequency in respect to all CD4
+ cells, but
were dramatically decreased in terms of their absolute cell number
(Figure 1C, D). These results show that normal NF-kB activity is
required for the development and homeostasis of Treg cells. The
profound decrease in the total Treg cell numbers in the spleen
might be enhanced due to the strong reduction of all mature CD4
+
T lymphocytes in the periphery of IkBa-SR Tg mice and their
impaired IL-2 production (Figure 1C, upper panel).
Supplementation of IkBa-SR Tg mice with IL-2 does not
rescue thymic Treg cells
Common-gamma chain cytokines, especially IL-2, are impor-
tant for the development and homeostasis of Treg cells. Treg cells
themselves are unable to produce IL-2 and are dependent on
paracrine IL-2, which is predominantly produced by activated T
helper cells [3]. Hence, CD4
+CD25
+ Tregs are diminished in IL-
2Rb
2/2 mice [30]. Additionally, Treg frequencies as well as
numbers are reduced by about 50% in IL-2
2/2 and CD25
2/2
mice [32,60]. It has been shown that NF-kB activation is
important for IL-2 expression [61,62] and that mice lacking
different components of the NF-kB signaling pathway, such as
NF-kB in Treg Cell Development
PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e20003Figure 1. Treg cell numbers are reduced in IkBa-SR Tg mice. Single-cell suspensions from thymus and spleen of wild-type (WT) and IkBa-
‘‘SuperRepressor’’ transgenic (IkB-SR Tg) mice were stained with CD4, CD8, CD25, and Foxp3 antibodies and analyzed by flow cytometry. (A, C)
Representative dot plots from one of three independent experiments are shown. Expression profiles of CD4 versus CD8 (upper panels) and CD25
versus intracellular Foxp3 (gated on CD4 SP cells, lower panels) of thymocytes (A) and splenocytes (C) of WT and IkB-SR Tg mice. Numbers in the
quadrants indicate the percentages of cells. (B, D) Percentages of CD25
+Foxp3
+ Treg cells relative to CD4SP cells, as well as absolute numbers of Treg
cells in the thymus (B) and spleen (D) of individual WT and IkB-SR Tg mice are displayed. Each symbol represents an individual mouse. Data were
compiled from three independent experiments. In each experiment, organs from three mice per genotype were analyzed separately. Horizontal bars
represent the mean. Mann-Whitney U-test was used for statistical analyses. *, p#0.05; ***, p#0.001; ns, not significant.
doi:10.1371/journal.pone.0020003.g001
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2/2, PCKh
2/2, MALT1
2/2, and CARMA1
2/2 mice,
secrete less IL-2 upon stimulation [43,46,47,51]. As expected,
lymphocytes from thymus and spleen of IkBa-SR Tg mice
secreted significantly less IL-2 upon mitogen stimulation as
determined by ELISA (Figure 2A, Figure S2A). Therefore, we
investigated if the reduced numbers of Treg cells in IkBa-SR Tg
mice are due to an insufficient supply of IL-2 from conventional T
cells. Wild-type as well as IkBa-SR Tg mice were injected with IL-
2 for two days to analyze the effect on Treg cell development. This
rather short treatment period was initially chosen to minimize any
unwanted ‘‘side-effects’’ due to non-physiologically high IL-2 levels
which might then skew the effect of the IL-2 supplementation on
Treg cell development. Flow cytometric analyses revealed that
percentages and numbers of CD25
+Foxp3
2CD4SP cytokine-
responsive thymic Treg precursor cells remained unaltered after
administration of exogenous IL-2 (Figure 2B, C). In contrast, IL-
2 significantly increased the frequencies as well as total cell
numbers of mature CD25
+Foxp3
+CD4SP thymic Treg cells in
IkBa-SR Tg mice, whereas thymic Treg cells from wild-type
control mice were only slightly affected (Figure 2B, D).
Exogenous IL-2 considerably increased the frequencies and the
absolute cell numbers of splenic CD25
+Foxp3
+CD4
+ Treg cells
both in wild-type and IkBa-SR Tg mice. In IkBa-SR Tg mice the
frequency of Treg cells almost reached wild-type levels (Figure
S2B, C).
In a second experiment we extended the treatment period to
sevendays,sinceinjectionofIL-2foronlytwodaysmaybetooshort
to fully reverse the observed developmental defect in the thymus in
IkBa-SR Tg mice. Flow cytometric analyses confirmed unaltered
frequencies and absolute numbers of CD25
+Foxp3
2CD4SP
cytokine-responsive thymic Treg precursor cells as well as
significantly elevated percentages and total numbers of Treg cells
in the thymus of IkBa-SR Tg mice (Figure S3A, B). Similar to the
results obtained after two days of treatment, thymic Treg cell
numbers did not reach wild-type levels (Figure S3A, B). The defect
in the periphery of IkBa-SR Tg mice was also not completely
reversed following this prolonged IL-2 treatment although splenic
Treg cells were further increased regarding frequencies and total
cell numbers in wild-type and IkBa-SR Tg mice when compared to
the shorter treatment period (Figure S3C).
Several studies have shown that signaling through the high
affinity IL-2 receptor (IL-2R) is important for Treg cell
development and homeostasis. Mice deficient in components of
proximal IL-2R signaling display remarkably reduced numbers of
Treg cells in the thymus and the periphery, as it was published for
T cell-specific STAT5ab-deficient mice [35,36]. Moreover,
transgenic mice expressing a constitutively active STAT5b show
a profound increase in Treg cell numbers, and transgene
expression can even restore Treg cell numbers in the absence of
IL-2 [35,39]. Therefore, we wanted to investigate if the impaired
Treg cell development in IkBa-SR Tg mice could be due to
restrained IL-2 signal transduction, in addition to IL-2 deprivation
and subsequent proliferative defects. Total thymocytes from wild-
type and IkBa-SR Tg mice were isolated and in vitro stimulated
with IL-2. Total cell lysates were prepared and STAT5
phosphorylation was detected using western blot analyses
(Material and Methods S1). The tyrosine phosphorylation status
of STAT5 in thymocytes from IkBa-SR Tg mice was comparable
to that of wild-type thymocytes (Figure S4). The expression level of
total STAT5 was also not altered (Figure S4).
In summary, conventional T cells from IkBa-SR Tg mice
secreted less IL-2 upon stimulation. However, the supplementation
with exogenous IL-2 could only partially rescue thymic Treg cell
numbers, although thymocytes from IkBa-SR Tg mice displayed
an intact IL-2R signaling. More importantly, IL-2 did not
significantly increase the numbers of Treg precursor cells,
suggesting that the Treg cell developmental defect can not be
exclusively referred to a proliferation defect caused by decreased
availability of IL-2.
The defect in Treg cell development in IkBa-SR Tg mice is
Treg cell-intrinsic
It has been shown previously that mice deficient in components
of the NF-kB signaling pathway, such as PCKh
2/2, Bcl10
2/2,
and CARMA1
2/2 mice [48,49,50,51], or deficient in NF-kB/Rel
proteins like p50
2/2c-Rel
2/2 double-deficient, c-Rel
2/2,
IKKb
2/2, and NF-kB1
SSAA/SSAA mice [52,53,54,55,56] display
impaired Treg cell development. Due to inhibition of NF-kB
activation, deficiencies in any of these molecules primarily resulted
in reduced IL-2 production by conventional T cells. In addition,
NF-kB activation is also involved in the differentiation of various
other hematopoietic cells that may contribute to normal Treg cell
development [40]. Because we were not able to fully restore Treg
cell numbers in IkBa-SR Tg mice by adding exogenous IL-2, we
generated mixed bone marrow chimeras to investigate whether
Treg cell-intrinsic rather than extrinsic defects are responsible for
the Treg cell phenotype in IkBa-SR Tg mice. In these chimeric
mice, wild-type derived cells can provide all potentially necessary
extrinsic factors such as cytokines and surface receptor ligands for
cell-cell interactions. Bone marrow cells from CD45.2
+ IkBa-SR
Tg mice were mixed with equal cell numbers from CD45.1
+ wild-
type mice and intravenously injected into lethally irradiated
Rag1
2/2 mice. Mice engrafted with only CD45.1
+ wild-type bone
marrow cells served as controls. Ten to twelve weeks after
reconstitution the mice were analyzed by flow cytometry. We
observed comparable percentages of lymphocyte subpopulations
in wild-type chimeras and mixed bone marrow chimeras (Figure
S5A), indicating normal lymphopoiesis in mixed bone marrow
chimeras. Furthermore, both IkBa-SR Tg and wild-type bone
marrow equally reconstituted DP and CD4SP thymocytes (Figure
S5B), as well as B220
+IgM
+ B cells in spleen and peripheral blood
(Figure S5C, D) depicted by the 1:1 ratio of contributing cells to
the given populations. In contrast, we observed that IkBa-SR Tg-
derived bone marrow cells contributed significantly less to thymic
CD8SP, peripheral CD4
+ and CD8
+ T cell populations in the
spleen and peripheral blood, both in respect to frequencies as well
as absolute cell numbers (Figure S5C, D). Importantly, bone
marrow from IkBa-SR Tg mice yielded markedly fewer
Foxp3
+CD4SP thymic Treg cells in the mixed bone marrow
chimeras, with respect to frequency and absolute cell number
(Figure 3A, B, C). Interestingly, the frequency of CD25
+Foxp3
+
peripheral Treg cells within the IkBa-SR Tg bone marrow-
derived CD4SP T cell compartment was similar to the one in the
wild-type derived CD4SP T cell compartment, both in the spleen
and peripheral blood (Figure 3A). Consistent with the profound
reduction in the total cell number of IkBa-SR Tg-derived CD4
+
peripheral T cells (Figure S5C), the percentage of IkBa-SR Tg
bone marrow cells contributing to the total Treg cell pool in the
periphery was below 20% (Figure 3B). Concomitantly, the total
number of IkBa-SR-derived peripheral Treg cells in the spleen
were also significantly reduced compared to wild-type derived ones
(Figure 3C).
Collectively, these data show that the impaired thymic
generation of Treg cells in IkBa-SR Tg mice is rather due to a
Treg cell-intrinsic defect than an extrinsic one, because it cannot
be compensated despite the presence of wild-type derived T
lymphocytes and soluble factors.
NF-kB in Treg Cell Development
PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e20003Figure 2. IL-2 can only partially rescue Treg cell numbers in the thymus of IkBa-SR Tg mice. (A) Thymocytes from wild-type (WT) and
IkBa-‘‘SuperRepressor’’ transgenic (IkB-SR Tg) mice were either left untreated (2) or stimulated (+) with PMA and ionomycin for 24 h. The IL-2
concentrations in the supernatants were determined by ELISA. IL-2 secretion from unstimulated cells was below the detection limit. Mean values and
SD were calculated from triplicates. Student’s t test was used for statistical analyses. *, p#0.05. (B, C, D) Wild-type and IkB-SR Tg mice were injected
either with IL-2 or PBS every 8 h for 2 days and thymi were analyzed by flow cytometry. (B) Representative dot plots from one of three independent
experiments are shown. Numbers in the quadrants represent the percentages of cells among CD4SP thymocytes from untreated (PBS) and IL-2
treated mice. (C) Percentages of CD25
+Foxp3
2 cytokine-responsive Treg precursor cells among CD4SP thymocytes, as well as their absolute numbers
in the thymus. (D) Percentages of CD25
+Foxp3
+ mature Treg cells among CD4SP thymocytes, as well as their absolute numbers. (B, C, D) Data were
NF-kB in Treg Cell Development
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development and homeostasis
IKKb-mediated NF-kB activation is crucial for the develop-
ment of Treg cells. On the one hand side, mice with a T cell-
specific ablation of IKKb show drastically reduced thymic as well
as peripheral CD4
+CD25
+ Treg cells [55]; on the other hand side,
transgenic mice expressing a constitutively active IKKb in T cells,
display increased proportions and numbers of Foxp3
+ cells in the
thymus [57]. Therefore, we investigated whether pharmacological
IKKb-inhibition impacts on Treg cell development and homeo-
stasis. AS602868, an anilinopyrimidine derivative and ATP
competitor, reversibly inhibits IKKb [63]. Wild-type mice either
received AS602868 or vehicle twice a day by oral gavage. Nuclear
extracts from AS602868 treated animals revealed an attenuation
of thymic and splenic nuclear NF-kB DNA binding activity by
approximately 35% and 45%, respectively, as determined by
ELISA (Figure S6A). There were no significant alterations in
absolute cell numbers of lymphocyte subpopulations in thymus
and spleen (Figure S6B, D). Furthermore, T cell development
appeared unaffected by AS602868 as supported by normal cell
distributions of thymocyte subpopulations. The percentages and
total numbers of CD4
2CD8
2 double-negative (DN), DP, CD4SP
and CD8SP cells closely resembled those of vehicle treated animals
(Figure S6C). AS602868 treatment did also not markedly alter the
proportions and total numbers of peripheral CD4
+ and CD8
+ T
cells in the spleen, except for a trend towards decreased total cell
numbers of both cell types (Figure S6E). However, application of
the IKKb inhibitor AS602868 for 7 days resulted in a significantly
decreased frequency of the thymic CD25
+Foxp3
+CD4SP Treg cell
compartment (Figure 4A). Moreover, IKKb-inhibition led to
slightly, but significantly reduced percentages of Treg cells in the
spleen (Figure 4B).
Figure 3. Treg cell development is intrinsically impaired in thymocytes overexpressing an IkBa-‘‘SuperRepressor’’. Mixed bone
marrow chimeras were generated by either injecting equal numbers of CD45.1
+C57BL/6 wild-type and CD45.2
+IkB-SR Tg bone marrow cells (mixed
chimera, n=5) or just CD45.1
+C57BL/6 wild-type bone marrow cells (WT chimera, n=3) into lethally irradiated Rag1
2/2 recipient mice. Ten weeks
later, Treg populations were examined in thymus, spleen and peripheral blood by flow cytometry. (A) Percentages of Treg cells in respect to CD45.1
+
or CD45.2
+ CD4SP cells as indicated in organs of mixed chimeras. Connected symbols indicate values from the same mouse. (B, C). Contributions of
wild-type (CD45.1
+) and IkB-SR Tg derived (CD45.2
+) cells to the total Treg cell populations in thymus, spleen, and peripheral blood of mixed
chimeras. Depicted are the mean values of percentages (B) as well as absolute cell numbers + SD (C) of contributing cells in the Treg population. Data
are representative of two independent experiments with similar numbers of mice in each experimental group. Mann-Whitney U-test was used for
statistical analyses. **, p#0.01; ns, not significant.
doi:10.1371/journal.pone.0020003.g003
compiled from two independent experiments with three mice per genotype and treatment in each experiment. Each symbol represents an individual
mouse. Horizontal bars represent the mean. Mann-Whitney U-test was used for statistical analyses. *, p#0.05; ns, not significant.
doi:10.1371/journal.pone.0020003.g002
NF-kB in Treg Cell Development
PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e20003These results implicate that pharmacological IKKb-inhibition
leads to impairments in the development of Treg cells even after
short periods of application, while leaving other T cell subpop-
ulations unaffected.
Discussion
The NF-kB signaling pathway was suspected to be crucially
involved in the development of naturally occurring Treg cells,
because mice lacking molecules of proximal TCR signaling
leading to NF-kB activation, such as PCKh, Bcl10, or CARMA1,
show marked defects in the thymic generation of Treg cells
[48,49,50,51]. Furthermore, mice with genetic ablations of IKKb
or NF-kB proteins like p50
2/2c-Rel
2/2 double-deficient or c-
Rel
2/2 mice display profoundly reduced numbers of
CD4
+Foxp3
+ Treg cells in thymus and periphery, whereas
conventional T cell populations remain largely unaltered
[52,53,54,55,56]. Finally, in transgenic mice with either elevated
or attenuated NF-kB activation, the numbers of CD4
+Foxp3
+
Treg cells are increased or decreased, respectively [57]. In this
study we investigated whether this developmental defect is Treg
cell-intrinsic or due to extrinsic effects such as insufficient IL-2
secretion by conventional T cells. Our data demonstrate that the
impaired thymic Treg cell development in IkBa-SR Tg mice
results mainly from a Treg cell-intrinsic defect.
We confirmed a reduced frequency and number of
CD4
+CD25
+Foxp3
+ Treg cells due to diminished NF-kB
activation in thymus and spleen of IkBa-SR Tg mice. Our
observations are in line with a previous study by Long et al.,
although they found a normal peripheral Treg cell frequency in
IkBa-SR Tg mice resulting in just a trend towards decreased Treg
cell numbers in the spleen [57]. This observation could be due to
age differences of the mice, as Treg cell numbers significantly
increase with age [64,65]. Moderately reduced thymic but
unaltered peripheral frequencies of Treg cells have also been
described for IkBaDNTg mice [62] expressing a truncated form of
IkBa, which is refractory to signal-induced degradation [59,66].
Total CD4
+ T cell and Treg cell numbers were markedly
decreased in the spleens of IkBaDNTg mice [66]. Similarly, in
IkBa-SR Tg mice we found markedly decreased splenic CD4
+ T
cell numbers, in addition to the previously described strongly
diminished CD8SP thymocytes and peripheral T cells [58]. In
spite of the decreased absolute number, the frequency of
peripheral Treg cells among all CD4
+ T cells was largely
preserved due to the also decreased CD4
+ T cell count.
Naturally occurring Treg cells cannot produce IL-2 and are
therefore dependent on paracrine IL-2, secreted from conven-
tional T cells [3]. Mice deficient in IL-2 or CD25 show reduced
numbers of Foxp3
+ Treg cells [32,67]. Additionally, IL-2Rb
2/2,
IL2
2/2IL15
2/2 double-deficient as well as IL-2Rc
2/2 mice are
characterized by a drastic loss of thymic and peripheral Treg cells
[30,33,60]. Administration of a neutralizing anti-IL-2 antibody to
neonatal mice reduced Treg cell numbers substantially [68].
According to the previously published two-step model, thymic
Treg cell development is governed by both TCR and IL-2
signaling, converging in STAT5 activation, which initiates Foxp3
Figure 4. Pharmacological NF-kB inhibition impairs thymic Treg cell development. Wild-type mice either received the IKKb-inhibitor
AS602868 (30 mg/kg) or vehicle twice a day for 7 days and thymus and spleen were analyzed by flow cytometry. Representative dot plots from one
of three independent experiments are shown (upper panel). Numbers in the quadrants represent the percentages of CD25
+Foxp3
+ cells among
CD4SP cells in thymus (A) and spleen (B) from untreated (Vehicle) and treated mice (AS602868). Percentages of CD25
+Foxp3
+ Treg cells among
CD4SP cells of individual mice are displayed (lower panel). Data are representative of three independent experiments with equal numbers of mice in
each experimental group. Each symbol represents an individual mouse. Horizontal bars represent the mean. Mann-Whitney U-test was used for
statistical analyses. *, p#0.05; **, p#0.01; ns, not significant.
doi:10.1371/journal.pone.0020003.g004
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cytokine-responsive CD25
+Foxp3
2CD4SP thymic Treg precursor
cells when NF-kB activation is attenuated within the T cell lineage.
Our data are in line with the two-step model, as strong TCR
signaling is necessary for precursor induction. TCR-induced NF-
kB activation appears to be involved in that process. Still, it
remained unclear whether NF-kB activation is only required for
the generation of Treg precursor cells or also at later stages of
thymic Treg cell development and proliferation. There was a
reduction by approximately 50% in thymic Treg precursor cells
compared to 70% in mature CD25
+Foxp3
+CD4SP thymic Treg
cells in IkBa-SR Tg mice. Possibly, NF-kB-deficient precursor
cells progress less efficiently to mature Tregs than their wild-type
counterparts. Additionally, survival and proliferation of the mature
Treg cells could be impaired. This might be due to a lack of IL-2,
since NF-kB activation is mandatory for normal IL-2 production
[43,46,47,51,55,61,62,69], or due to a defect in IL-2R signaling
converging in STAT5 activation [33]. Our observations argue
against IL-2 deprivation as the only reason for impaired thymic
Treg cell differentiation in IkBa-SR Tg mice. Although IL-2
secretion was significantly diminished in IkBa-SR Tg mice,
administration of IL-2 for two and seven days could only partially
restore thymic Treg cell numbers and did not influence the
decreased numbers of Treg precursor cells. This is in line with data
from Molinero et al. also showing that exogenous IL-2 could not
reverse the low numbers of thymic Treg cells in CARMA1
2/2
mice [51]. Moreover, restoring NF-kB activity through expression
of a constitutively active IKKb transgene could regenerate the
completelackofthymicTregcellsinTAK1
2/2and CARMA1
2/2
mice without rescuing the development of conventional peripheral
T cells as predominant IL-2 producers [57]. Notably, CYLD
2/2
mice failed to restore Treg cell numbers in CARMA1
2/2 mice,
although exhibiting constitutive NF-kB activation [59]. The latter
study argues for two different NF-kB signaling pathways being
involved in these two mouse models.
We did not find any evidence for impaired IL-2R signaling in
thymocytes from IkBa-SR Tg mice. Hence, it is unlikely that
thymic Treg precursor cells are not able to respond properly to IL-
2. Similarly, transgenic expression of IkBaDN was reported to
have no impact on proximal IL-2R signaling in total thymocytes
[59]. Reciprocally, transgenically enhanced NF-kB signaling did
neither increase cc-receptor expression nor responsiveness to cc-
cytokines [57]. In contrast, two other studies have provided
evidence that impaired NF-kB signaling can result in attenuated
proximal IL-2R signaling. IkBaDNTg mice exhibited a striking
defect in thymic STAT5a activation [70], and NF-kB
SSAA/SSAA
Knock-in mice, expressing a p105 mutant resistant to signal-
induced degradation, also displayed a IL-2R signaling defect in
peripheral T cells [56]. The reasons for these discrepancies remain
to be elucidated.
Mixed bone marrow chimeras established a Treg cell-intrinsic
requirement for NF-kB activation as the presence of both wild-
type derived soluble factors and hematopoietic cells could not
restore thymic Treg cell development of IkBa-SR Tg cells. The
dramatic reduction of Treg cells in PKCh
2/2, Bcl-10
2/2, and c-
Rel
2/2 mice was also referred to a Treg cell-intrinsic defect
[53,54,57,71]. Together, these data clearly argue against a
predominantly indirect role of NF-kB activation in thymic Treg
cell development. Instead, normal Treg-cell intrinsic NF-kB
activation seems to be mandatory to facilitate the generation of
thymic Treg precursor cells, possibly via enhancing/prolonging
the necessary TCR signal, and to further support their
susceptibility towards cytokine stimulation. Most importantly, the
NF-kB pathway is directly involved in promoting Foxp3
expression, as c-Rel can bind to the CNS1 element (conserved
noncoding sequence) within the promoter region, as well as to the
CNS3 enhancer element, thereby initiating chromatin remodeling
and leading to an open chromatin conformation at the foxp3 locus
[57]. In addition, Ruan et al. reported that c-Rel, via binding to the
foxp3 promoter, induces the formation of an ‘‘enhanceosome’’
through the recruitment of other transcription factors which
subsequently engage histone-modifying enzymes and finally turn
on Foxp3 expression [71]. Interestingly, as soon as Foxp3 is
expressed in developing Treg, it may counteract the transcrip-
tional activity of NF-kB by direct interaction [72].
The reduced thymic output of mature Treg cells may account
partially for diminished peripheral Treg cell numbers in IkBa-SR
Tg mice. However, recombinant IL-2 provoked a strong
proliferative response in peripheral Treg cells of IkBa-SR Tg
mice, resulting in an increase of Treg frequencies, comparable to
those of wild-type mice. Moreover, in mixed bone marrow
chimeras the frequencies of IkBa-SR-derived, peripheral Treg
cells within the IkBa-SR-derived T cell compartment closely
resembled those derived from wild-type bone marrow. These data
may indicate that wild-type bone marrow-derived conventional T
cells supplied sufficient IL-2 to promote expansion also of IkBa-
SR Tg-derived Treg cells. The relatively low numbers of IkBa-
SR-derived peripheral CD4
+ T cells may be rather due to
impaired proliferation or survival, whereas peripheral IkBa-SR-
derived Treg cells might be low due to decreased thymic output.
Thus, in the periphery NF-kB activation seems to be more
important for inducing IL-2 production by conventional T cells,
instead of contributing cell-intrinsically to Treg cell homeostasis.
Treg cell-intrinsic NF-kB activation was further reported to be
dispensable for peripheral Treg cell conversion by TGF-b
[50,53,73], suggesting that different intracellular signaling path-
ways are involved in thymic and peripheral Treg cell generation.
These reports are in contrast to observations that c-Rel
2/2 mice
are indeed to some degree impaired in peripheral Treg cell
conversion, possibly due to their defective IL-2 production as Treg
cell conversion could be partially rescued by exogenous IL-2
[71,74].
Treg cells are important for controlling autoimmune diseases,
allergy and graft rejection. They play a conflictive role in
preventing anti-tumor responses as well as in clearing viral
infections [75]. Manipulation of Treg cell differentiation is
therefore in the centre of intensive research. Here we demon-
strated that pharmacological IKKb-inhibition via AS602868
markedly diminished Treg cell frequencies in thymus and also
slightly, but significantly reduced Treg cell frequencies in spleens
of mice, without detectable toxicity for conventional T cell
subpopulations. Recent data proved also beneficial effects of
AS602868 in treating various forms of cancer, as well as non-
alcoholic steatohepatitis in animal models [76,77].
It was previously shown that prolonged high-dose pharmaco-
logical IKKb-inhibition results in enhanced pro-IL-1b processing
and elevated IL-1b concentrations [78], which in turn might favor
the generation of pro-inflammatory Th17 cells [79,80]. Despite
the inhibitory effects of IKKb-blockade on Treg cell development
and the potential promotion of Th17 cells, it appears unlikely that
incomplete pharmacological IKKb-inhibition fosters pro-inflam-
matory responses, the more so as many pro-inflammatory factors
such as cytokines, chemokines and adhesion molecules are
expressed in an NF-kB-dependent manner and are affected by
IKKb-inhibition. In fact, pharmacological IKKb-inhibition was
reported to induce beneficial effects in various animal models of
inflammatory diseases like collagen-induced arthritis [81] and
MOG33–55-induced experimental autoimmune encephalomyelitis
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was not investigated in those studies. Our findings implicate that at
least short-term or transient systemic NF-kB inhibition resulting in
reduced Treg cell generation might be a promising treatment
strategy for diseases in which Treg cells negatively influence
diseases’ outcomes. Especially in cancer, IKKb inhibitors may act
in a dual way, first via directly impairing NF-kB-dependent
survival mechanisms in the malignant cell itself, second via
fostering the anti-cancer immune response by inhibition of Treg
development.
In summary, we did not only show that Treg cell-intrinsic NF-
kB activation is mandatory for thymic Treg cell development, but
our observations also suggest that pharmacological IKKb-
inhibition might be beneficial for the treatment of diseases
aggravated by Treg cells.
Materials and Methods
Ethics Statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies, and all animal work was approved by the
government of Mittelfranken (Regierung von Mittelfranken
approval no. 54-2532.1-13/08 and TS-04/4 Med. III-IZKF N2).
Mice
Transgenic mice expressing a stabilized form of IkBa (IkBa-SR
Tg) have been described earlier [58]. C57BL/6 RAG1-deficient
mice (Rag1
2/2) and CD45.1 congenic C57BL/6 mice were kindly
provided by Dr. Thomas Winkler (Department of Genetics,
University of Erlangen-Nuremberg, Germany). C57BL/6J and
BALB/cJ mice were purchased from Janvier S.A.S., Le Genest-St-
Isle, France. Mice used for analysis were 4–6 weeks old, unless
otherwise noted. All animals were housed under pathogen-free
conditions in the animal facility of the University of Erlangen-
Nu ¨rnberg.
Flow cytometric analyses
Single-cell suspensions were obtained from bone marrow, thymi
and spleens of mice via gentle homogenization of organs through
nylon mesh filters (BD Pharmingen, San Jose, CA). For surface
staining typically 1610
6 lymphocytes were incubated at 4uC for
30 min with fluorochrome-conjugated monoclonal antibodies
against CD4, CD8, CD25, CD45.1, CD45.2, Streptavidin-PerCP,
Streptavidin-PE (BD Pharmingen, San Jose, CA, USA) in PBS
containing 2% FBS (Gibco, Invitrogen Life technologies, Karls-
ruhe, Germany). Intracellular FOXP3 staining was performed
with a FOXP3 antibody together with the ‘‘FOXP3 Staining
Buffer Set’’ (Miltenyi Biotec, Bergisch Gladbach, Germany)
according to the manufacturer’s instructions. Labeled cells were
analyzed on a FACSCalibur flow cytometer (BD Pharmingen, San
Jose, CA). Data were analyzed using the FlowJo Software (Tree
Star Inc., Ashland, OR, USA).
Cytokine Quantification by ELISA
Thymocytes and splenocytes from IkBa-SR Tg and C57BL/6
wild-type mice (2610
5/well) were cultured in triplicates in 96-well
U-bottom plates in 200 ml of complete RPMI (RPMI 1640
containing 10% FBS, 2 mM L-glutamine, 1 mM sodium-pyru-
vate, 50 mM b-mercaptoethanol, 100 U/ml penicillin, 100 mg/ml
streptomycin, Gibco, Invitrogen Life technologies, Karlsruhe,
Germany). The cells were either left untreated or stimulated with
PMA (50 ng/ml) and ionomycin (1 mM) (Calbiochem, Merck
KGaA, Darmstadt, Germany) for 24 h. Supernatants from these
cultures were assayed by sandwich ELISA (‘‘Mouse IL-2 ELISA
Ready-SET-Go!’’, eBioscience, NatuTec GmbH, Frankfurt,
Germany) according to the manufacturer’s instructions. IL-2
levels were quantified by comparison to standards supplied by the
manufacturer.
Treatment of mice with recombinant IL-2
IkBa-SR Tg or C57BL/6 wild-type mice were intraperitoneally
injected with recombinant human (rh) IL-2 (2 mg/injection,
Proleukin, Novartis, Emeryville, CA, USA) resuspended in PBS
or with PBS alone every 8 h for 2 days (total of 6 injections) or
every 12 h for 7 days (total of 14 injections). Thymi and spleens
were analyzed on day 3 or day 8, respectively, by flow cytometry.
Mixed radiation bone marrow chimera
Bone marrow cells from the femurs of 6-week old CD45.2
+
IkBa-SR Tg (1.5610
6) and CD45.1
+ C57BL/6 (1.5610
6) wild-
type donor mice were mixed at a ratio of 1:1. A total of 3.0610
6
cells were injected intravenously into 6-week old lethally irradiated
(950 rads) C57BL/6 Rag1
2/2 recipient mice 24 h after irradia-
tion. Control mice received bone marrow from one genotype only.
Ten to twelve weeks after bone marrow reconstitution the mice
were sacrificed and analyzed by flow cytometry.
Treatment of mice with the IKKb inhibitor AS602868
AS602868 (kindly provided by Merck Serono S.A., Geneva,
Switzerland) is an anilinopyrimidine derivative and adenosine
triphosphate (ATP) competitor, which inhibits IKKb. AS602868
was dissolved in a saline solution containing 0.5% Carboxymeth-
ylcellulose and 0.25% Tween-80 (Sigma-Aldrich, St. Louis, MO,
USA) as vehicle. Mice received the IKKb-inhibitor AS602868 by
oral gavage at a dose of 30 mg/kg twice a day for 7 days. Control
mice just received vehicle at the same frequencies. Thymi and
spleens were analyzed on day 8 by flow cytometry.
Statistical analysis
Statistical analyses were performed using either the two-tailed
student’s t test for heteroscedastic samples or Mann-Whitney U test
for unpaired samples as appropriate and indicated in the figure
legends. All statistical analyses were calculated with the Graph Pad
Prism 5.0 software. p#0.05 was considered as statistically
significant. Error bars in the figures represent standard deviations
(SD).
Supporting Information
Figure S1 Inhibition of NF-kB activation in transgenic
mice expressing a mutated IkBa as ‘‘SuperRepressor’’
of NF-kB. (A) Total cell lysates from thymocytes and splenocytes
of wild-type (WT) and IkBa-‘‘SuperRepressor’’ transgenic (IkB-SR
Tg) mice were analyzed for expression of the endogenous IkBa
(IkB WT) and the slower migrating HA-tagged transgenic IkBa
(HA-IkB Tg) by western blot analysis (upper panels). b-actin served
as loading control (lower panels). (B) Total thymocytes from WT
and IkB-SR Tg mice were either left untreated (2) or stimulated
(+) with PMA and ionomycin. Nuclear extracts were prepared and
EMSAs were performed using IRDye
700-labelled oligonucleotides
for NF-kB (upper panel), and for Oct-1 (lower panel) as loading
control. (C) NF-kB DNA-binding activity in nuclear extracts from
thymocytes stimulated as described in (B) was determined by
ELISA via binding of NF-kB/Rel proteins to an NF-kB
oligonucleotide. The data are representative of three independent
experiments using different nuclear extracts prepared from
different mice. Mean values and SD were calculated from
NF-kB in Treg Cell Development
PLoS ONE | www.plosone.org 9 May 2011 | Volume 6 | Issue 5 | e20003triplicates. Student’s t test for unpaired samples was used for
statistical analyses. *, p#0.05; ns, not significant.
(TIF)
Figure S2 IL-2 increases the proportion and total cell
number of peripheral Treg cells. (A) Splenocytes from wild-
type (WT) and IkBa-‘‘SuperRepressor’’ transgenic (IkB-SR Tg)
mice were either left untreated (2) or stimulated (+) with PMA and
ionomycin as described for Figure 2. The IL-2 concentrations in the
supernatants were determined by ELISA. IL-2 secretion from
unstimulated cells was below the detection limit. Mean values and
SD were calculated from triplicates. Student’s t test was used for
statistical analyses. *, p#0.05. (B, C, D) WT and IkB-SR Tg mice
were injected either with IL-2 or PBS as described for Figure 2. On
day 3, splenocytes were analyzed by flow cytometry. (B)
Representative dot plots from one of three experiments are shown.
Numbers in the plots represent the percentage of CD25
+Foxp3
+
cells among CD4SP splenocytes from untreated (PBS) and IL-2
treated mice. (C) Percentages of CD25
+Foxp3
+ Treg cells among
CD4SP cells, as well as absolute numbers of Treg cells in the spleen
are displayed. Data were compiled from two independent
experiments with three mice per genotype and treatment in each
experiment. Each symbol represents an individual mouse. Hori-
zontal bars represent the mean. Mann-Whitney U-test was used for
statistical analyses. *, p#0.05; **, p#0.01; ns, not significant.
(TIF)
Figure S3 Prolonged IL-2 treatment can only partially
rescue Treg cell development and homeostasis. Wild-type
(WT) and IkBa-‘‘Superrepressor’’ transgenic (IkB-SR Tg) mice
were injected either with (rh)IL-2 or PBS every 12 h for 7 days.
On day 8, the impact on Treg cell development and homeostasis
was analyzed by flow cytometry. (A) Percentages of CD25
+Foxp3
2
cytokine-responsive Treg precursor cells relative to CD4SP
thymocytes, as well as their absolute numbers in the thymus.
(B) Percentages of CD25
+Foxp3
+ Treg cells relative to CD4SP
thymocytes, as well as absolute numbers of Treg cells in the
thymus. (C) Percentages of CD25
+Foxp3
+ Treg cells among
CD4SP cells, as well as absolute numbers of Treg cells in the
spleen. (A, B, C) Each symbol represents an individual mouse.
Horizontal bars represent the mean. Mann-Whitney U-test was
used for statistical analyses. *, p#0.05; ns, not significant.
(TIF)
Figure S4 Thymocytes from IkBa-SR Tg mice show no
IL-2 signaling defect. Thymocytes from WT and IkBa-
‘‘SuperRepressor’’ transgenic (IkB-SR Tg) mice were either left
untreated (2) or were stimulated with IL-2 (+). Total cell lysates
were analyzed for activated, phosphorylated STAT5ab (p-STAT5,
upper panel) by western blot analysis. Total STAT5 expression
(STAT5, lower panel) served as loading control. The data are
representative of three independent experiments using different
total cell lysates prepared from different thymocytes cultures.
(TIF)
Figure S5 T and B cell development in mixed bone
marrow chimeras. Mixed bone marrow chimeras were
generated as described for Figure 3. (A) Mean percentages + SD
of indicated lymphocyte populations in thymus, spleen and
peripheral blood in WT chimeras (n=3) and mixed bone marrow
chimeras (n=5). DP, CD4
+CD8
+; DN, CD4
2CD8
2; SP, single
positive, Treg, CD4
+Foxp3
+ (thymus) or CD4
+CD25
+Foxp3
+
(spleen, blood). (B, C, D). Contributions of wild-type- (CD45.1
+)
and IkBa-SR Tg-derived (CD45.2
+) cells to the given cell
populations in thymus (B), spleen (C), and peripheral blood (D)
of mixed chimeras. Depicted are the mean percentages + SD (left
panels), as well as absolute cell numbers + SD (right panels) of cells
contributing to the indicated populations. Data are representative
of two independent experiments with similar numbers of mice in
each experimental group. Mann-Whitney U-test was used for
statistical analyses. *, p#0.05, **, p#0.01; ns, not significant.
(TIF)
Figure S6 Nuclear NF-kB activity and T cell develop-
ment in AS602868 treated mice. Wild-type mice either
received the IKKb-inhibitor AS602868 or vehicle as described for
Figure 4. (A) The NF-kB DNA-binding activity in nuclear extracts
from thymocytes and splenocytes of untreated (Vehicle) and
treated mice (AS602868) was determined by ELISA via p65
binding to an NF-kB oligonucleotide. Mean values and SD were
calculated from pentaplicates. Student’s t test was used for
statistical analyses. *, p#0.05; ns, not significant (B–E) Single-
cell suspensions from thymus and spleen of untreated (Vehicle) and
treated mice (AS602868) were analyzed by flow cytometry. Total
cell numbers in thymus (B) and spleen (D) are displayed. Each
symbol represents an individual mouse. (C, E) Representative dot
plots from one of three independent experiments are shown.
Numbers in the quadrants indicate the percentages of cells relative
to total live cells in the lymphocyte gate (upper panel). Mean
Percentages (middle panel) and mean absolute numbers (low
panel) of T cell subpopulations in thymus (C) and spleen (E) are
depicted. DP, CD4
+CD8
+; DN, CD4
2CD8
2.( A–E) Data are
representative of three independent experiments with equal
numbers of mice. Horizontal bars represent the mean (B, D)
+SD (A, C, E). Mann-Whitney U-test was used for statistical
analyses. *, p#0.05; ns, not significant.
(TIF)
Material and Methods S1 Detailed description of the methods
Western blotting, Electromobility shift assay (EMSA), NF-kB transcription
factor assay.
(DOC)
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